Skip Navigation Links

Bookmark and Share
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma

on 7/21/2021
--Phase III trial will evaluate progression-free survival and overall survival of patients with recurrent glioblastoma --Glioblastoma has an incidence rate of approximately 2.85 to 4.56 per 100,000 population ...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.